Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?

Basit Öğe Kaydı
dc.contributor.authorBozkurt, Oktay
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorDuzkopru, Yakup
dc.contributor.authorUysal, Mukremin
dc.contributor.authorKaraca, Halit
dc.contributor.authorBerk, Veli
dc.date.accessioned2024-04-24T16:11:02Z
dc.date.available2024-04-24T16:11:02Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractAlthough there has been an increase in overall and progression-free survival with the use of novel targeted therapies in metastatic renal cell carcinoma (mRCC) in recent times, predictive markers to determine which patients would benefit from tyrosine kinase inhibitor therapies are needed. The late recurrence might be a predictive marker for response to sunitinib treatment in patients with mRCC. Background: We investigated the clinicopathological features in patients with recurrent renal cell carcinoma (RCC) within 5 years or more than 5 years after nephrectomy and determined predictors of overall survival (OS) and progression-free survival (PFS) after disease recurrence in the administration of first-line sunitinib in the treatment of metastatic RCC (mRCC). Patients and Methods: In this study we enrolled 86 Turkish patients with mRCC who received sunitinib. Univariate analyses were performed using the log rank test. Results: Fifty-six patients (65%) were diagnosed with disease recurrence within 5 years after radical nephrectomy (early recurrence) and 30 patients (35%) were diagnosed with recurrence more than 5 years after radical nephrectomy (late recurrence). Fuhrman grade was statistically significantly different between the 2 groups (P = .013). The late recurrence patients were significantly associated with the Memorial Sloan Kettering Cancer Center favorable risk group compared with patients with early recurrence (p = .001). There was a statistically significant correlation between recurrence time and the rate of objective remission (ORR) (the late recurrence group vs. the early recurrence group: 43.3% vs. 14.3%, respectively; P = .004). From the time of disease recurrence, the median OS was 42.0 (95% confidence interval [CI], 24.4-59.5) months in the late recurrence group, and 16 (95% CI, 11.5-20.4) months in the early recurrence group (P = .001). Median PFS was 8(95% CI, 4.05-11.9) months in the early recurrence group, and 20 (95% CI, 14.8-25.1) months in the late recurrence group (P <= .001). Conclusion: The study demonstrated a potential prognostic value of late recurrence in terms of PFS, OS, and ORR. (C) 2015 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.clgc.2015.07.005
dc.identifier.endpage554en_US
dc.identifier.issn1558-7673
dc.identifier.issn1938-0682
dc.identifier.issue6en_US
dc.identifier.pmid26320661
dc.identifier.scopus2-s2.0-84947864292
dc.identifier.scopusqualityQ1
dc.identifier.startpage548en_US
dc.identifier.urihttps://doi.org/10.1016/j.clgc.2015.07.005
dc.identifier.urihttps://hdl.handle.net/11468/15240
dc.identifier.volume13en_US
dc.identifier.wosWOS:000365633700009
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherCig Media Group, Lpen_US
dc.relation.ispartofClinical Genitourinary Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLate Recurrenceen_US
dc.subjectPrognostic Factoren_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectSunitiniben_US
dc.subjectSurvivalen_US
dc.titleIs Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?en_US
dc.titleIs Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu